Northwest Biotherapeutics reported $6.54M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agenus USD 6.21M 4.34M Mar/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Celldex Therapeutics USD 13.1M 1.65M Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Merck USD 2.89B 219M Jun/2026
Northwest Biotherapeutics USD 6.54M 534K Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Plus Therapeutics USD 4.26M 779K Mar/2026
Roche Holding CHF 6.37B 908M Jun/2026